2013年1月26日 星期六

有科學依據的養生食物





[Save in the BLOG for future references]


http://www.medscape.com/features/slideshow/brainfood2013?src=ptalk#11


The Best Foods for the Brain: An
Update




It has been nearly a year since Medscape
published
Brain Food, a look at how what we eat influences our mental
and neurologic health. Since then, our understanding of how diet affects the
brain has grown significantly. The current slideshow, based primarily on
Medscape news coverage, reviews the previous year's studies on nutrition and
brain health.




Diet for Depression




Research
from the past several years suggests that consumption of monounsaturated fatty
acids (found in olive oil, avocados, and nuts), polyunsaturated fatty acids
(PUFAs; found in nuts, seeds, fish, and leafy green vegetables), and
supplements containing eicosapentaenoic acid decreases depression risk over
time.[1-3] To that end, adhering to
Mediterranean
dietary patterns
specifically -- that is, a diet rich in fruits,
vegetables, nuts, whole grains, and fish and high in unsaturated fat -- is
associated with a 30% reduction in depression risk, compared with meat- and
dairy-heavy diets and diets high in trans-fatty acids; intake of the latter is
associated with an increased depression risk over time.[4] Conversely,
low levels of PUFAs may increase the risk of developing postpartum depression,
according to
a 2012 literature review published in the Canadian
Journal of Psychiatry
.[5] Keep in mind, however, that
although there is strong evidence of an association between diet and
depression,
most
studies
to date have not proven causality, supporting the need for large,
randomized primary prevention trials.[6]




Rethinking Fat




Beyond reducing depression risk, the
unsaturated fatty acids common in the Mediterranean diet have other benefits
for the brain. A
2012 review published in Pediatrics reported on
the evidence linking PUFA deficiency to attention-deficit/hyperactivity
disorder, as well as findings from trials where these fats were used
successfully to address ADHD symptoms.[7] Another small
study
showed that increasing omega-3 fatty acid consumption enhances working memory
in young adults.[8] Previous work has linked Mediterranean
diets high in olive oil consumption with a lower risk for
ischemic
stroke,
[9,10] mild cognitive impairment, and Alzheimer
disease
, and particularly the latter two when associated with high levels
of physical activity.[11,12]




Fruit to Fend Off Stroke




2012 was a good year for fruit. An analysis
from the Nurses' Health Study found that high consumption of flavanones, a
flavanoid subclass found in high concentrations in grapefruits and oranges, is
associated with a 19% lower risk for ischemic stroke in women.[18]
A
Finnish
study
[19] published in Neurology reported that
a diet high in lycopene, a potent antioxidant found in tomatoes, may cut stroke
risk in men. Previous work has shown that polyphenols, namely anthocyanins,
found in berries and other darkly pigmented fruits and vegetables may slow
cognitive decline by inducing autophagy (a process by which cells clear
proteinaceous debris linked to memory loss) and reduce cardiovascular disease
risk by reducing oxidative stress and attenuating inflammatory gene expression.[20-22] Each of these studies points to the importance of a
healthy diet high in plant foods and low in processed foods for a range of
health outcomes, both physical and mental.




Cut the Soda, Keep Up the Coffee




2012 saw more evidence that coffee might be
the
original
wonder drug
. A new observational study[23] to be presented
at the American Academy of Neurology meeting in March shows that people who
drink 4 cups of coffee a day are 10% less likely to develop depression. Those
who opted for 4 or more servings a day of diet soda or fruit punch were 30% and
38% more likely, respectively, to develop depression. Past work also
suggests that the world's most widely used stimulant cuts depression risk,
possibly by altering serotonin and dopamine activity and through its
antioxidant and anti-inflammatory properties.[24-27]




Alcohol: Always in Moderation




The Greeks touted "nothing in
excess," a refrain that still rings true: Low to moderate* alcohol
consumption has been associated with numerous potential physiologic benefits
with neurologic implications, including improved cholesterol profiles,
beneficial effects on platelet and clotting function, and improved insulin sensitivity.[28] Last year
we reported
that limited alcohol use is associated with a lower risk for dementia[28,29] and that moderate alcohol -- especially antioxidant-rich
red wine -- intake may protect against cerebrovascular disease.[30-32]
A new study published in Circulation Research found that dealcoholized
Merlot reduced blood pressure by approximately 6/3 mm Hg in a sample of 67 men
at high cardiovascular risk, suggesting that the beneficial effects of wine
consumption may not strictly be due to its alcohol content.[33]
However, the health costs to the brain of alcohol consumption can quickly
outweigh the benefits, as heavy and long-term alcohol use can lead to alcohol
abuse and dependence, impair memory function, contribute to neurodegenerative
disease, and hinder psychosocial functioning.




*The US Food and Drug Administration
defines "moderate alcohol consumption" as up to 1 drink per day for
women and up to 2 drinks per day for men. One drink is equivalent to 12 fluid
ounces of regular beer, 5 fluid ounces of 12% alcohol wine, or 1.5 fluid ounces
of distilled spirits.




Chocolate -- and Still More
Antioxidants




Many recent studies have added to the already
robust body of evidence suggesting that dark, flavonol-rich chocolate may have
cardiovascular benefits. A
meta-analysis published in Cochrane Database of
Systematic Reviews
reported that individuals who consumed 100 g of dark
chocolate every day -- a standard Hershey bar weighs 43 g -- saw an average
blood pressure drop of 2.77/2.20 mm Hg compared with control participants.[34] A
study out of Finland[35] published in Neurology
reported that individuals who eat at least 52 g of chocolate per week have a
17% lower risk for stroke, compared with those who eat less than 12 g a week.
The flavonols in dark chocolate likely contribute to the reported benefits by
scavenging free radicals and improving endothelial and platelet function. But
always check the label, as some processed chocolate contains trans-fats, which
should be avoided.




What Not to Eat: Cut the Carbs




Various 2012 studies further clarified how
overly sweet, unhealthy foods affect the brain. An
animal study[36] out of UCLA found that diets high in fructose can impair
cognitive function, which is reversible with omega-3 fatty acid
supplementation. Coauthor Fernando Gomez-Pinilla, PhD, told Medscape
Medical News
, "High fructose consumption can induce some signs of
metabolic syndrome in the brain and can disrupt the signalling of the insulin
receptors and reduce the action of insulin in the brain."
Other work[37] published in JAMA suggests that fructose
consumption modulates the neurophysiologic pathways involved in appetite
regulation and encourages overeating. An October 2012
study[38] published in the Journal of Alzheimer's Disease reported
that a diet high in carbohydrates and sugar raises the risk for mild cognitive
impairment in the elderly, while a diet high in fat and protein may reduce this
risk. Lead author Rosebud O. Roberts, MD, an epidemiologist at Mayo
Clinic in Rochester, Minnesota, commented to Medscape Medical News
that an "optimal balance" of carbohydrates, fat, and protein may help
"maintain neuronal integrity and optimal cognitive function in the
elderly."




What Not to Eat (cont)




Mounting evidence in 2012 reinforces that
high consumption of red meat increases stroke risk. The
largest
meta-analysis
to date[39] looking at the atherogenic
effects of red meat found that the risk for total stroke increased by up to 13%
for each increase in a single serving of fresh, processed, and total amount of
red meat consumed per day. Earlier in the year another study[40]
found that processed and unprocessed red meat is associated with a higher risk
for stroke, while poultry was associated with a reduced risk. A study by
Sánchez-Villegas and colleagues[4] found that a diet high
in fruits, vegetables, grains, and fish led to a 30% lower depression risk
compared with a meaty diet. But, as we pointed out last year, meat quality
might be a factor: Moderate consumption of unprocessed, free-range red meat may
actually protect against depression and anxiety.[41] Mental
health nutrition expert Dr. Felice Jacka, a research fellow at Deakin
University in Geelong, Australia, comments in this report that despite the
growing locavore movement, much of the livestock in the United States is raised
on industrial feedlots, which "...increases saturated fat and decreases
very important good fatty acids...pasture-raised animals have a much healthier
fatty acid profile."




References





  1. Sánchez-Villegas
    A, Verberne L, De Irala J, et al. Dietary fat intake and the risk of
    depression: the SUN project. PLoS One. 2011;6:e16268.

  2. Sánchez-Villegas
    A, Toledo E, de Irala J, Ruiz-Canela M, Pla-Vidal J, Martínez-González MA.
    Fast-food and commercial baked goods consumption and the risk of
    depression. Public Health Nutr. 2012;15:424-432.

  3. Sublette
    ME, Ellis S, Geant AL, Mann JJ. Meta-analysis of the effects of
    eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin
    Psychiatry. 2011;72:1577-1584.

  4. Sánchez-Villegas
    A, Delgado-Rodríguez M, Alonso A, et al. Association of the Mediterranean
    dietary pattern with the incidence of depression: the Seguimiento
    Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch
    Gen Psychiatry. 2009;66:1090-1098.

  5. Pierre
    JM. Mental illness and mental health: is the glass half empty or half
    full? Can J Psychiatry. 2012;57:704-712.

  6. Sanchez-Villegas
    A, Martinez-Gonzalez MA. Diet, a new target to prevent depression? BMC
    Med. 2013;11:3. [Epub ahead of print]

  7. Millichap
    JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics.
    2012;129:330-337.

  8. Narendran
    R, Frankle WG, Mason NS, Muldoon MF, Moghaddam B. Improved working memory
    but no effect on striatal vesicular monoamine transporter type 2 after
    omega-3 polyunsaturated fatty acid supplementation. PLoS One. 2012;7:e46832.

  9. Fung
    TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. Mediterranean
    diet and incidence of and mortality from coronary heart disease and stroke
    in women. Circulation. 2009;119:1093-1100.

  10. Kastorini
    CM, Milionis HJ, Ioannidi A, et al. Adherence to the Mediterranean diet in
    relation to acute coronary syndrome or stroke nonfatal events: a
    comparative analysis of a case/case-control study. Am Heart J.
    2011;162:717-724.

  11. Scarmeas
    N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean
    diet and mild cognitive impairment. Arch Neurol. 2009;66:216-225.

  12. Scarmeas
    N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of
    Alzheimer disease. JAMA. 2009;302:627-637.

  13. Chowdhury
    R, Stevens S, Gorman D, et al. Association between fish consumption, long
    chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic
    review and meta-analysis. BMJ. 2012 Oct 30;345:e6698.

  14. Hedelin
    M, Löf M, Olsson M, et al. Dietary intake of fish, omega-3, omega-6
    polyunsaturated fatty acids and vitamin D and the prevalence of
    psychotic-like symptoms in a cohort of 33000 women from the general
    population. BMC Psychiatry. 2010;10:38.

  15. Sanchez-Villegas
    A, Henriquez P, Figueiras A, et al. Long chain omega-3 fatty acids intake,
    fish consumption and mental disorders in the SUN cohort study. Eur J Nutr.
    2007;46:337-346.

  16. Jacka
    FN, Pasco JA, Williams LJ, Meyer BJ, Digger R, Berk M. Dietary intake of
    fish and PUFA, and clinical depressive and anxiety disorders in women.
    Br J Nutr. 2012 Oct 10:1-8.
    [Epub ahead of print]

  17. Amminger
    GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for
    indicated prevention of psychotic disorders: a randomized,
    placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.

  18. Cassidy
    A, Rimm EB, O'Reilly EJ, et al. Dietary flavonoids and risk of stroke in
    women. Stroke. 2012;43:946-951.

  19. Karppi
    J, Laukkanen JA, Sivenius J. Serum lycopene decreases the risk of stroke
    in men. Neurology. 2012;79:1540-1547.

  20. Brooks
    M. New mechanism for berries' potential brain benefits uncovered. Medscape
    Medical News. August 31, 2010.
    http://www.medscape.com/viewarticle/727764
    Accessed January 10, 2013.

  21. Polouse
    S. Berry extracts and brain aging: clearance of toxic protein accumulation
    in brain via induction of autophagy. Program and abstracts of the 240th
    National Meeting of the American Chemical Society; August 22-26, 2012;
    Boston, Massachusetts. Abstract 60.

  22. Basu
    A, Rhone M, Lyons TJ. Berries: emerging impact on cardiovascular health.
    Nutr Rev. 2010;68:168-177.

  23. Chen
    H. Sweetened beverages, coffee and tea in relation to depression among
    older US adults. American Academy of Neurology 65th Annual Meeting; March
    16-23, 2013; San Diego, California. Abstract 2257.

  24. Lucas
    M, Mirzaei F, Pan A, et al. Coffee, caffeine, and risk of depression among
    women. Arch Intern Med. 2011;171:1571-1578.

  25. Pasco
    JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity
    C-reactive protein with de novo major depression. Br J Psychiatry.
    2010;197:372-377.

  26. Ng
    F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders:
    evidence base and therapeutic implications. Int J Neuropsychopharmacol.
    2008;11:851-876.

  27. O'Connor
    A. Coffee drinking linked to less depression in women. New York Times.
    February 13, 2012.
    http://well.blogs.nytimes.com/2011/09/26/coffee-drinking-linked-to-less-depression-in-women/
    Accessed January 11, 2013.

  28. Wayerer
    S, Schäufele M, Wiese B, et al; German AgeCoDe Study group (German Study
    on Ageing, Cognition and Dementia in Primary Care Patients). Current
    alcohol consumption and its relationship to incident dementia: results
    from a 3-year follow-up study among primary care attenders aged 75 years
    and older. Age Ageing. 2011;40:456-463.

  29. Peters
    R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and
    cognitive decline in the elderly: a systematic review. Age Ageing.
    2008;37:505-512.

  30. de
    Gaetano G, Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB. A meta-analysis
    of studies on wine and beer and cardiovascular disease. Pathophysiol
    Haemost Thromb. 2002;32:353-355.

  31. Matos
    RS, Baroncini LA, Précoma LB, et al. Resveratrol causes antiatherogenic
    effects in an animal model of atherosclerosis. Arq Bras Cardiol.
    2012;98:136-142.

  32. Bertelli
    AA, Das DK. Grapes, wines, resveratrol, and hearth health. J Cardiovasc
    Pharmacol. 2009;54:468-476.

  33. Chiva-Blanch
    G, Urpi-Sarda M, Ros E, et al. Dealcoholized red wine decreases systolic
    and diastolic blood pressure and increases plasma nitric oxide: short
    communication. Circ Res. 2012;111:1065-1068.

  34. Ried
    K, Sullivan TR, Fakler P, et al. Effect of cocoa on blood pressure.
    Cochrane Database Syst Rev. 2012; DOI: 10.1002/14651858.CD008893.pub2

  35. Larsson
    SC, Virtamo J, Wolk A. Chocolate consumption and risk of stroke: a
    prospective cohort of men and meta-analysis. Neurology. 2012;79:1223-1229.

  36. Agrawal
    R, Gomez-Pinilla F. 'Metabolic syndrome' in the brain: deficiency in
    omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling
    and cognition. J Physiol. 2012;590:2485-2499.

  37. Page
    KA, Chan O, Arora J, et al. Effects of fructose vs glucose on regional
    cerebral blood flow in brain regions involved with appetite and reward
    pathways. JAMA. 2013;309:63-70, 85-86.

  38. Roberts
    RO, Roberts LA, Geda YE, et al. Relative intake of macronutrients impacts
    risk of mild cognitive impairment or dementia. J Alzheimes Dis.
    2012;32:329-339.

  39. Kaluza
    J, Wolk A, Larsson S. Red meat consumption and risk of stroke. Stroke.
    2012;43:2556-2560.

  40. Bernstein
    AM, Pan A, Rexrode KM, et al. Dietary protein sources and the risk of
    stroke in men and women. Stroke. 2012;43:637-644.

  41. Jacka
    FN, Pasco JA, Williams LJ, et al. Red meat consumption and mood and
    anxiety disorders. Psychother Psychosom. 2012;81:196-198.






Which
Foods Are Best for the Brain?





Diet is
inextricably linked to conditions such as heart disease, obesity, and diabetes.
However, what we consume also seems to have significant implications for the
brain: Unhealthy diets may increase risk for psychiatric and neurologic
conditions, such as depression and dementia, whereas healthy diets may be
protective. Based primarily on recent Medscape News coverage, the following
slideshow collects some of the more prominent investigations on nutrition and
the brain into a single resource to aid in counseling your patients.





Make
for Malta in Depression, Stroke, and Dementia





A 2009 study
published in Archives of General Psychiatry found that people who follow
Mediterranean dietary patterns -- that is, a diet high in fruits, vegetables,
nuts, whole grains, fish, and unsaturated fat (common in olive and other plant
oils) -- are up to 30% less likely to develop depression than those who
typically consume meatier, dairy-heavy fare.
[1] The olive oil-inclined also show a lower risk for ischemic stroke[2,3] and are less likely
to develop mild cognitive impairment and Alzheimer disease, particularly when
they engage in higher levels of physical activity.
[4,5]





Fat:
The Good and the Bad





A study conducted in
Spain
[6,7] reported that consumption of both polyunsaturated fatty acids
(found in nuts, seeds, fish, and leafy green vegetables) and monounsaturated
fatty acids (found in olive oil, avocados, and nuts) decreases the risk for
depression over time. However, there were clear dose-response relationships
between dietary intake of trans fats and depression risk, whereas other data
support an association between trans fats and ischemic stroke risk.
[8] Trans fats are found extensively
in processed foods, including many commercial chocolates (hence, check that
label when considering the chocolate slide below). A deficiency in
polyunsaturated fatty acids has been linked
to attention deficit/hyperactivity disorder in children.
[9]





Fish
Oil to Fend Off Psychosis?





Thanks to their
high levels of polyunsaturated fatty acids, namely omega-3 fatty acids, fish
can help fend off numerous diseases of the brain. A 2010 study
correlated fish consumption with a lower risk for psychotic symptoms,
[10] and concurrent work suggested that
fish oil may help prevent psychosis in high-risk individuals.
[11] Although data are conflicting,
new research shows that the omega-3 fatty acids eicosapentaenoic acid and
docosahexaenoic acid are beneficial in depression and postpartum
depression
, respectively, and other research suggests that omega-3
deficiency may be a risk factor for suicide.
[12-16]
Oily, cold-water fish, such as
salmon, herring, and mackerel, have the highest omega-3 levels.





Berries
for Oxidative Stress





Polyphenols,
namely anthocyanins, found in berries and other darkly pigmented fruits and
vegetables may slow cognitive decline through antioxidant and anti-inflammatory
properties. A study in rats from 2010 showed that a diet high in strawberry,
blueberry, or blackberry extract leads to a "reversal of age-related
deficits in nerve function and behavior involving learning and memory."
[17] In vitro work by the same group
found that strawberry, blueberry, and acai berry extracts -- albeit in very
high concentrations -- can induce autophagy, a means by which cells clear
debris, such as proteins linked to mental decline and memory loss.
[18] Berry anthocyanins may also reduce
cardiovascular disease risk by reducing oxidative stress and attenuating
inflammatory gene expression.
[19]





A
"Whole" Diet: Make Room for Red Meat?





A so-called
"whole" diet high in fruits, vegetables, whole grains, and
high-quality meats and fish results in a 30% risk reduction for depression and
anxiety disorders, compared with consumption of a "Western diet" high
in processed foods and saturated fats, according to a 2010 study.
[20] Even unprocessed red meat seems to
be protective against depressive and anxiety disorders,
[21] in contrast to many studies in
which red meat often falls into the category of "unhealthy" food. In
speaking with Medscape News, principal investigator Dr. Felice Jacka
specifically addressed the importance of farming practices: Despite the growing
locavore movement, much of the livestock in the United States is still raised
on industrial feedlots, which "...increases saturated fat and decreases
very important good fatty acids...pasture-raised animals have a much healthier
fatty acid profile." A "whole" dietary pattern may also reduce
depression risk, as assessed at 5-year follow-up.
[22]








有科學依據的養生之豆--咖啡



Medscape教育資料,附參考文獻[須存檔]: 


Coffee: The Original Wonder Drug?




July
24, 2012




 Mental
and Medical Benefits of Coffee: Introduction




The
best part of waking up...is reducing your risk of neurodegeneration. And
depression, and cancer, and cardiovascular disease... It's becoming increasingly
clear that coffee is more than just a morning routine. The body of data
suggesting that the world's most widely used stimulant is beneficial in a
variety of mental and medical conditions is growing at a staggering rate. A
recent study published in the New England Journal of Medicine found that
coffee consumption lowered all-cause mortality by over 10% at 13-year
follow-up.
[1] Based primarily on recent Medscape Medical News
coverage, the following slideshow reviews the potential medical and psychiatric
benefits of coffee consumption




Cardiovascular Disease




It may seem counterintuitive: A substance
known to increase blood pressure might actually be good for your cardiovascular
system. Caffeine consumption can cause a short-lived increase in blood pressure
– a major risk factor for cardiovascular disease (CVD) – and regular use has
been linked to a longer-term increase. However, when caffeine is ingested via
coffee, enduring blood pressure elevations are small and CVD risks may be
balanced by protective properties. Coffee beans contain antioxidant compounds
that reduce oxidation of low-density lipoprotein (LDL) cholesterol and coffee
consumption has been associated with reduced concentrations of inflammatory
markers.[2-7] Moderate coffee intake was associated with a lower
risk for coronary heart disease as far out as 10 years,[3] and
new data
suggest that an average of 2 cups a day protects against heart failure.[8]




Photo courtesy of Thinkstock




Cerebrovascular Disease and Stroke




The vascular benefits of coffee are not lost
on the brain. According to a
2011
meta-analysis,
consuming between 1 and 6 cups a day reportedly cut stroke
risk by 17%.[9] A 22% to 25% risk reduction was seen in a
large sample
of Swedish women followed for an average of 10 years.[10] And while
coffee's impact on stroke risk in those with CVD is still in question, a
meta-analysis
presented at the European Meeting on Hypertension 2012 found that 1 to 3 cups a
day may protect against ischemic stroke in the general population.[11]




 




Diabetes
and Weight Loss




Despite
coffee's association with increased blood pressure, the steamy brew appears to
benefit other aspects of so-called “metabolic syndrome,” the dangerous cluster
of hypertension, hyperglycemia, abnormal lipid levels, and increased body fat.
Numerous studies have linked regular coffee drinking with improved glucose
metabolism, insulin secretion, and a significantly reduced risk for
type 2 diabetes.[12-14]
Preliminary data from an
ongoing study also suggest that coffee consumption can
promote weight loss. Overweight patients treated with unroasted coffee beans in
supplement form lost an average of 17 pounds over 22 weeks. The study authors
suspect that this effect may be due in part to coffee containing chlorogenic
acid, a plant compound with antioxidant properties thought to reduce glucose
absorption.
[15]




 




Cancer




With so many ingestibles thought to increase
cancer risk – soda, grilled meat, all things pickled – at least we can rest
easy when it comes to coffee (according to recent data, anyway). Evidence
suggests that moderate to heavy coffee consumption can reduce the risk for
numerous cancers, including
endometrial (> 4 cups/day),[16] prostate
(6 cups/day),[17]
head and neck
(4 cups/day),[18,19]
basal cell
carcinoma
(> 3 cups/day),[20] and estrogen receptor-negative breast cancer
(> 5 cups/day).[21] The benefits are thought to be at least
partially due to coffee's antioxidant and antimutagenic properties.[16,18]




Neurodegeneration




It's clear that coffee temporarily affects
cognition – try getting through morning rounds without a cup. But new research
also links coffee with more enduring effects on cognitive well-being. A
study
published in the Journal of Alzheimer's Disease showed that patients
with mild cognitive impairment and plasma caffeine levels of > 1200 ng/mL –
courtesy of ~3 to 5 cups of coffee a day – avoided progression to dementia over
the following 2 to 4 years. [22] Corresponding studies in mice suggest
that caffeine suppresses enzymes involved in amyloid-beta production, while
coffee consumption boosts G-CSF, interleukin-10, and interleukin-6 levels,
cytokines thought to contribute to the reported benefits. Caffeinated coffee
has long been thought to be neuroprotective in Parkinson disease (PD), and
recent work
found that variants in the glutamate-receptor gene GRIN2A affect PD risk in
coffee drinkers.[23] Furthermore,
data
presented at this year's American Academy of Neurology Annual Meeting showed
that 3 cups of coffee a day may prevent the formation of Lewy bodies, a
signature preclinical pathologic finding in PD.[24] Despite the
encouraging associations in neurodegenerative disease, caffeine intake has also
been associated with accelerating age of onset of
Huntington
disease
.[25]




Depression




A 2011 study
suggests that a boost in coffee consumption might also benefit our mental
health[26]: Women who drank 2 to 3 cups of coffee per day had a 15%
decreased risk for depression compared with those who drank less than 1 cup per
week. A 20% decreased risk was seen in those who drank 4 cups or more per day.
The short-term effect of coffee on mood may be due to altered serotonin and
dopamine activity, whereas the mechanisms behind its potential long-term
effects on mood may relate to its antioxidant and anti-inflammatory properties,
factors that are thought to play a role in depressive illnesses.[26-29]




Liver Disease




The liver might help break down coffee, but
coffee might protect the liver (in some cases). Evidence suggests that coffee
consumption slows disease progression in patients with alcoholic cirrhosis and
hepatitis C and reduces the risk of developing hepatocellular carcinoma.[30-33]
A 2012
study
reported that coffee intake is associated with a lower risk for
nonalcoholic fatty liver disease (NAFLD),[34] while
other recent
work
found that coffee protects against liver fibrosis in those with
already established NAFLD.[32]




But That's Not All...




A grab-bag of other research suggests that
coffee intake may relieve
dry-eye syndrome by increasing tear production,[35]
reduce the risk for
gout,[36] and potentially fight infection.[37]
Coffee and hot tea consumption
were found
to be protective against one of the medical community's most concerning bugs,
methicillin-resistant Staphylococcus aureus (MRSA).[37]
While it remains unclear whether the beverages have systemic antimicrobial activity,
study participants who reported any consumption of either were approximately
half as likely to have MRSA in their nasal passages.




And Finally, the Risks




As is often the case, with the benefits come
the risks, and coffee consumption certainly has negative medical and
psychiatric effects to consider. Besides the aforementioned potential increase
in blood pressure, coffee can incite or worsen anxiety, insomnia, and tremor
and potentially elevate
glaucoma risk.[38] Also, given the potential
severity of symptoms, caffeine withdrawal syndrome is
under
consideration
for inclusion in the forthcoming DSM-5.[39]




Additional research is necessary to better
assess and balance the potential benefits and drawbacks of coffee consumption.
But mounting evidence suggests that going back for a second cup might not
necessarily be a bad decision.




Author




Bret Stetka, MD, Editorial Director, Medscape from WebMD




Disclosure:
Bret Stetka, MD, has disclosed no relevant financial
relationships.




References




  1. Freedman
    ND, Park Y, Abnet CC, et al. Association of coffee drinking with total and
    cause-specific mortality. N Engl J Med. 2012;366:1891-1904.
    Abstract

  2. Larsson
    SC, Orsini N. Coffee consumption and risk of stroke: a dose-response
    meta-analysis of prospective studies. Am J Epidemiol. 2011;174:993-1001.
    Abstract

  3. Wu JN, Ho
    SC, Zhou C, et al. Coffee consumption and risk of coronary heart diseases:
    a meta-analysis of 21 prospective cohort studies. Int J Cardiol.
    2009;137:216-225.
    Abstract

  4. Natella F,
    Nardini M, Belelli F, et al. Coffee drinking induces incorporation of
    phenolic acids into LDL and increases the resistance of LDL to ex vivo
    oxidation in humans. Am J Clin Nutr. 2007;86:604-609.
    Abstract

  5. Gómez-Ruiz
    JA, Leake DS, Ames JM. In vitro antioxidant activity of coffee compounds
    and their metabolites. J Agric Food Chem. 2007;55:6962-6969.
    Abstract

  6. Nardini M,
    D'Aquino M, Tomassi G, et al. Inhibition of human low-density lipoprotein
    oxidation by caffeic acid and other hydroxycinnamic acid derivatives. Free
    Radic Biol Med. 1995;19:541-552.
    Abstract

  7. Montagnana
    M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue
    does not take center stage. Semin Thromb Hemost. 2012;38:164-177.
    Abstract

  8. Mostofsky
    E, Rice MS, Levitan EB, Mittleman MA. Habitual coffee consumption and risk
    of heart failure: a doseresponse
    meta-analysis. Circ Heart Fail.
    2012;DOI:10.1161/CIRCHEARTFAILURE.112.967299.
    http://circheartfailure.ahajournals.org

  9. Larsson
    SC, Orsini N. Coffee consumption and risk of stroke: a dose-response
    meta-analysis of prospective studies. Am J Epidemiol. 2011;174:993-1001.
    Abstract

  10. Larsson
    SC, Virtamo J, Wolk A. Coffee consumption and risk of stroke in women.
    Stroke. 2011;42:908-912.
    Abstract

  11. D'Elia L,
    Cairella G, Garbagnati F, et al. Moderate coffee consumption is associated
    with lower risk of stroke: meta-analysis of prospective studies. J
    Hypertension. 2012;30 (e-Supplement A):e107.

  12. Huxley R,
    Lee CM, Barzi F, et al. Coffee, decaffeinated coffee, and tea consumption
    in relation to incident type 2 diabetes mellitus: a systematic review with
    meta-analysis. Arch Intern Med. 2009;169:2053-2063.
    Abstract

  13. Sartorelli
    DS, Fagherazzi G, Balkau B, et al. Differential effects of coffee on the
    risk of type 2 diabetes according to meal consumption in a French cohort
    of women: the E3N/EPIC cohort study. Am J Clin Nutr. 2010;91:1002-112.
    Abstract

  14. Floegel A,
    Pischon T, Bermann MM, et al. Coffee consumption and risk of chronic
    disease in the European Prospective Investigation into Cancer and
    Nutrition (EPIC)Germany study. Am J Clin
    Nutr. 2012;95:901-908.
    Abstract

  15. Vinson JA,
    Burnham B, Nagendran MV, et al. Randomized double-blind placebo-controlled
    crossover study to evaluate the efficacy and safety of a green coffee bean
    extract in overweight subjects. Program and abstracts of the 243rd
    American Chemical Society National Meeting and Exposition; March 25-29,
    2012; San Diego, California. Abstract 92.

  16. Je Y,
    Hankison SE, Tworoger SS, et al. A prospective cohort study of coffee
    consumption and risk of endometrial cancer over a 26-year follow-up.
    Cancer Epidemiol Biomarkers Prev. 2011;20:1-9.

  17. Wilson KM,
    Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk
    and progression in the Health Professionals Follow-up Study. J Natl Cancer
    Inst. 2011;8;103:876-884.

  18. Turati F,
    Galeone C, La Vecchia C, et al. Coffee and cancers of the upper digestive
    and respiratory tracts: meta-analyses of observational studies. Ann Oncol.
    2011;22:536-544.
    Abstract

  19. Galeone C,
    Tavani A, Pelucchi C, et al. Coffee and tea intake and risk of head and
    neck cancer: pooled analysis in the international head and neck cancer
    epidemiology consortium. Cancer Epidemiol Biomarkers Prev.
    2010;19:1723-1736.
    Abstract

  20. Song F,
    Qureshi AA, Han J. Increased caffeine intake is associated with reduced
    risk of Basal cell carcinoma of the skin. Cancer Res. 2012;72:3282-3289.
    Abstract

  21. Li J,
    Seibold P, Chang-Claude J, et al. Coffee consumption modifies risk of estrogen-receptor
    negative breast cancer. Breast Cancer Res. 2011;13:R49.

  22. Cao C,
    Loewenstein DA, Lin X, et al. High blood caffeine levels in MCI linked to
    lack of progression to dementia. J Alzheimer Dis. 2012;30:559-572.

  23. Hamza TH,
    Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study
    identifies glutamate receptor gene GRIN2A as a Parkinson's disease
    modifier gene via interaction with coffee. PLoS Genet. 2011;7: e1002237.

  24. Ross W,
    Duda J, Abbott R, et al. Association of coffee caffeine consumption with
    brain Lewy pathology in the Honolulu-Asia Aging Study. Program and
    abstracts of the 64th Annual Meeting of the American Academy of Neurology;
    April 21-28, 2012; New Orleans, Louisiana. Abstract #S42.005.

  25. Duru C.
    Caffeine is a modifier of age at onset in Huntington's disease. Program
    and abstracts of the 15th International Congress of Parkinson's Disease
    and Movement Disorders; June 5-9, 2011; Toronto, Ontario, Canada. Abstract
    180.

  26. Lucas M,
    Mirzaei F, Pan A, et al. Coffee, caffeine, and risk of depression among
    women. Arch Intern Med. 2011;171:1571-1578.
    Abstract

  27. Pasco JA,
    Nicholson GC, Williams LJ, et al. Association of high-sensitivity
    C-reactive protein with de novo major depression. Br J Psychiatry.
    2010;197:372-377.
    Abstract

  28. Ng F, Berk
    M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence
    base and therapeutic implications. Int J Neuropsychopharmacol.
    2008;11:851-876.
    Abstract

  29. O'Connor
    A. Coffee drinking linked to less depression in women. New York Times.
    February 13, 2012.
    http://well.blogs.nytimes.com/2011/09/26/coffee-drinking-linked-to-less-depression-in-women/
    Accessed January 11, 2012.

  30. Molloy JW,
    Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of
    coffee and caffeine consumption with fatty liver disease, nonalcoholic
    steatohepatitis, and degree of hepatic fibrosis. Hepatology.
    2012;55:429-436.
    Abstract

  31. Gallus S,
    Tavani A, Negri E, La Vecchia C. Does coffee protect against liver
    cirrhosis? Ann Epidemiol. 2002;12:202-205.

  32. Molloy JW,
    Calcagno CJ, Williams CD, et al. Association of coffee and caffeine
    consumption with fatty liver disease, nonalcoholic steatohepatitis, and
    degree of hepatic fibrosis. Hepatology. 2012;55:429-436.
    Abstract

  33. Modi AA,
    Feld JJ, Park Y, et al. Increased caffeine consumption is associated with
    reduced hepatic fibrosis. Hepatology. 2010;51:201-209.
    Abstract

  34. Birerdinc
    A, Stepanova M, Pawloski L, Younossi M. Caffeine is protective in patients
    with non-alcoholic fatty liver disease. Aliment Pharmacol Ther.
    2012;3576-82.

  35. Arita R,
    Yanagi Y, Honda N, Maeda S, et al. Caffeine increases tear volume
    depending on polymorphisms within the adenosine A2a receptor gene and
    cytochrome P450 1A2. Ophthalmology. 2012;119:972-978.
    Abstract

  36. Choi HK,
    Willett W, Curhan G. Coffee consumption and risk of incident gout in men:
    A prospective study. Arthritis Rheum. 2007;56:2049-2055.
    Abstract

  37. Matheson
    EM, Mainous AG, Everett CJ, King DE. Tea and coffee consumption and MRSA
    nasal carriage. Ann Fam Med. 2011;9:299-304.
    Abstract

  38. Pasquale
    L. Program and abstracts of the American Glaucoma Society 22nd Annual
    Meeting; March 1-4, 2012; New York, New York. Abstracts 23 and 83.

  39. Compton
    WM, Budney AJ, Hasin D. New approaches to substance and related diagnoses
    in the DSM-5. Program and abstracts of the American Academy of Addiction
    Psychiatry (AAAP) 22nd Annual Meeting and Symposium; December 8-11, 2011;
    Scottsdale, Arizona. Workshop B2. Presented December 9, 2011.





Reviewers




Henry R. Black, MD, Clinical Professor of Internal Medicine;
Director, Hypertension Research, Center for the Prevention of Cardiovascular
Disease, New York University School of Medicine, New York, New York




Disclosure:
Henry R. Black, MD, has disclosed the following relevant
financial relationships: Served as a director, officer, partner, employee,
advisor, consultant, or trustee for: Novartis Pharmaceuticals Corporation; XOMA
US LLC; Daiichi Sankyo, Inc.; MSD; Mitsubishi Pharma America, Inc.; Ligand
Pharmaceuticals Incorporated; SERVIER; BioSante Pharmaceuticals Served as a
speaker or member of a speakers bureau for: Boehringer Ingelheim
Pharmaceuticals, Inc. Received income in an amount equal to or greater than
$250 from: Novartis Pharmaceuticals Corporation




Felice
N. Jacka, PhD, Associate Professor, Barwon Psychiatric Research Unit, Deakin
University, Geelong, Australia




Disclosure:
Felice N. Jacka, PhD, has disclosed no relevant financial
relationships.




 





2013年1月24日 星期四

不需要病毒或蛋 而製成的 Flu vaccine

FDA Okays Novel Flu Vaccine Made Without Eggs, Viruses

Robert Lowes


Jan 16, 2013

The US Food and Drug Administration (FDA) today approved Flublok (Protein Sciences), a trivalent seasonal influenza vaccine made with what the agency calls a "novel technology" that promises to surmount a number of pesky immunization challenges.


The manufacturing process for Flublok, indicated for adults ages 18 through 49, dispenses with eggs as well as influenza viruses, dispelling any fears of catching the flu from the vaccine. It instead relies on recombinant DNA technology and an insect virus expression system, making Flublok the first of its kind, according to the FDA. The process can quickly produce large quantities of an influenza virus protein called hemagglutinin (HA), the active ingredient in all inactivated influenza vaccines that makes it possible for the virus to enter cells. Most antibodies that prevent influenza infection target HA.


Flublok contains 3 recombinant HA proteins to protect against 2 influenza A virus strains — A(H3N2) and 2009 pandemic A(H1N1) — and one influenza B virus strain. The trivalent vaccine now in use for the 2012-2013 influenza season guards against the same 3 strains.


The FDA noted that Flublok's manufacturing process has already been harnessed to make vaccines against other infectious diseases besides influenza.


"The new technology offers the potential for faster start-up of the vaccine manufacturing process in the event of a pandemic because it is not dependent on an egg supply or on availability of the influenza virus," said Karen Midthun, MF, director of the FDA's Center for Biologics Evaluation and Research in a press release today.


The new vaccine holds other advantages over traditional counterparts, according to a press release issued by Protein Sciences. It is made without the mercury-containing preservative called thimerosal, a source of unfounded fears of mercury poisoning. Flublok also lacks any antibiotics and thus does not contribute to the growth of antibiotic-resistant pathogens.


In a study that compared Flublok to a placebo, the new vaccine proved 44.6% effective against all circulating influenza strains, not just those that matched what the vaccine was designed to cover.


The most commonly reported adverse events for Flublok are those that occur with traditional egg-based vaccines made with inactivated viruses. They include injection-site pain, headache, fatigue, and muscle aches.


Protein Sciences said that it will make a limited supply of Flublok available during the current influenza season. The vaccine will be widely available in the season to follow.


More information about Flublok is available on the FDA Web site.


2013年1月8日 星期二

第一個治療 HIV/AIDS 腹瀉的藥

FDA Approves First Antidiarrheal Drug for HIV/AIDS

Susan Jeffrey


Dec 31, 2012

The US Food and Drug Administration (FDA) today approved crofelemer ( Fulyzaq, Salix Pharmaceuticals under license from Napo Pharmaceuticals, Inc) to relieve diarrhea in patients with HIV/AIDS who are undergoing antiretroviral therapy.


Diarrhea is a common reason for patients with HIV/AIDS to stop or switch therapies, according to a news release from the FDA. The newly approved drug is intended for use in patients with HIV/AIDS whose diarrhea is not caused by infection by a virus, bacteria, or parasite. The drug is dosed twice daily to manage watery diarrhea caused by secretion of water and electrolytes in the gastrointestinal tract, the news release notes.


"Currently, there are no FDA-approved therapies for HIV-associated diarrhea," said Julie Beitz, MD, director of the Office of Drug Evaluation III in FDA's Center for Drug Evaluation and Research, in the release. "[Crofelemer] may be helpful to HIV/AIDS patients with this troublesome condition."


The new drug is derived from the red sap of the Croton lechleri plant and is only the second botanical prescription drug approved by FDA. A botanical drug product is often a complex mixture derived from 1 or more plant materials with varying degrees of purification, the FDA notes; manufacturers of botanical drugs are required to "ensure rigorous control of raw materials, and good agricultural and collection practices, together with analytical testing of the complex mixture," according to the news release.


In 2006, the FDA approved the first botanical prescription drug, sinecatechins ( Veregen, PharmaDerm), a treatment for external genital and perianal warts.


Crofelemer was first slated for approval September 5, but the review was delayed at that time by the FDA to accommodate further discussion between the agency and the manufacturer on ensuring compliance with the manufacturing and product quality requirements of the Food, Drug & Cosmetic Act.


Approval of crofelemer is based on a clinical trial of 374 HIV-positive patients receiving stable antiretroviral therapy with a history of diarrhea lasting 1 month or longer. The median number of daily watery bowel movements was 2.5 per day at baseline. Patients who had diarrhea caused by an infection or a gastrointestinal disease were excluded. The investigators randomly assigned patients to receive crofelemer or placebo twice daily.


The trial was designed to measure clinical response, defined as the number of patients who had 2 or fewer watery bowel movements weekly. Results showed that 17.6% of treated patients experienced clinical response compared with 8% of those receiving placebo. Crofelemer had a persistent antidiarrheal effect in some patients for up to 20 weeks.


"Before treating patients with [crofelemer], health care professionals should conduct proper testing to confirm the diarrhea is not caused by an infection or a gastrointestinal disease," the FDA release adds. "Common side effects reported in patients taking [crofelemer] in the clinical trial were upper respiratory tract infection, bronchitis, cough, flatulence, and increased levels of bilirubin."



葡萄球菌菌血症需要至少十四天抗生素治療

Uncomplicated S. aureus Bacteremia Needs 14 Days of Treatment

Jan 02, 2013

By Will Boggs, MD


NEW YORK (Reuters Health) Jan 02 - Uncomplicated Staphylococcus aureus bacteremia should be treated for at least 14 days to prevent relapse, Korean researchers say.


That matches the recommendation of the Infectious Diseases Society of America (IDSA) - but the researchers say that guideline was never formally evaluated in clinical studies.


The new study by Dr. Yang Soo Kim and colleagues from the University of Ulsan College of Medicine, Seoul, Korea involved 111 patients with uncomplicated S. aureus bacteremia.


Nearly half (53, 47.7%) had methicillin-resistant S. aureus (MRSA). Only two patients (1.8%) had community-acquired bacteremia, according to a report online December 17th in Antimicrobial Agents and Chemotherapy.


Patients received standard doses of antibiotics for S. aureus bacteremia, the authors said. Fifty-five of 58 patients with methicillin-susceptible S. aureus bacteremia received cefazolin (48.3%) or nafcillin (46.6%); the other three received vancomycin. Most patients with MRSA bacteremia (85%) received vancomycin; the others received teicoplanin or linezolid.


The combined rate of relapse and death was similar in patients treated for fewer than 14 days or for at least 14 days (26.3% vs 21.9%).


But relapse occurred only in patients treated for less than 14 days (p=0.036).


The only factor independently associated with treatment failure was a high Charlson comorbidity score, however. Duration of antibiotic therapy was not significantly associated with treatment failure in multivariate analysis.


"The relapse rate after short-course therapy for uncomplicated S. aureus bacteremia should be close to zero," the researchers say. "Therefore, the relapse rate of 7.9% in our study (with short course therapy) is not acceptable, and it seems reasonable that uncomplicated S. aureus bacteremia should be treated for at least 14 days."


"Because of increased risk for treatment failure," they add, "patients with a high Charlson comorbidity score or primary bacteremia, especially if it is community-acquired, should not be treated with short-course therapy."


"These recommendations need to be further evaluated in a large multicenter study," the researchers caution


Dr. Richard G. Wunderink, a pulmonary critical care physician Northwestern University in Chicago, told Reuters Health, "The issue with Staph bacteremia is that the source is often unknown and potentially uncontrolled. So some of these patients may have either occult endocarditis or some other form of endovascular infection."


"The other factor is that vancomycin is just not a very effective antibiotic," Dr. Wunderink said. "Whether longer treatment is needed with more bactericidal antibiotics such as daptomycin or ceftaroline for these uncomplicated bacteremia cases is still unknown."


"So the bottom line, from the standpoint of a Pulmonary/Critical Care physician with a strong bias against prolonged antibiotic courses, is that this study supports the current recommendation, and I don't see a compelling reason to change the recommendation," Dr. Wunderink concluded.


Dr. Kim did not respond to a request for comments on this report.


Antimicrob Agents Chemother 2012.


眼角膜炎先使用 Fluoroquinolones

 


Medscape Medical News


Fluoroquinolones First for Bacterial Keratitis

Troy Brown


Dec 28, 2012


 


Fluoroquinolones are a good first empiric treatment for patients with bacterial keratitis, according to a recent systematic review and meta-analysis.


Marie-Sophie Hanet, MD, from the Department of Ophthalmology at the University of Louvain, Brussels, and the Scientific Support Unit, CHU Mont-Godinne, Yvoir, Belgium, and colleagues published their findings in the December issue of the Canadian Journal of Ophthalmology.


Fluoroquinolones are readily available and are well-tolerated by patients, the authors write.


"Based on these data, it seems reasonable to consider fluoroquinolones as the initial empiric treatment in most cases of suspected bacterial keratitis, and the use of fortified antibiotics being restricted to eyes unresponsive to initial treatment and to the cases for which a pathogen resistant to fluoroquinolones has been identified," the authors note.


The researchers selected 13 comparative studies for inclusion in the review: 8 prospective randomized trials and 5 nonrandomized studies. Two of the randomized trials were large multicenter trials, involving 28 clinical centers, and the other 6 involved 1 or 2 centers.


Of the randomized studies, 4 case series compared patients treated with fluoroquinolones with either historical cases and/or a group of nonrandomized patients who were treated simultaneously with a standard fortified antibiotic regimen; there was also a single retrospective medical record analysis.


Therapeutic success was defined as healing (complete re-epithelialization) that occurred while receiving the assigned treatment; treatment failure was defined as treatment that had to be changed because the patient's condition worsened or failed to improve.


Most studies used time to healing as an additional efficacy end point, but it was defined differently in the studies reported.


Nonsignificant differences between fluoroquinolones and standard treatment were found in meta-analyses of treatment efficacy, with a trend toward favorability of fluoroquinolone treatment. Using a random-effects model, odds ratios were 1.473 (95% confidence interval [CI], 0.902 - 2.405) for all randomized and nonrandomized studies, 2.374 (95% CI, 1.082 - 5.205) for nonrandomized studies, 1.050 (95% CI, 0.636 - 1.732) for randomized studies, and 1.199 (95% CI, 0.477 - 3.011) for randomized studies that only included patients with a microbiology-confirmed bacterial infection.


Using a fixed-effects model, odds ratios were 1.374 (95% CI, 0.996 - 1.894) for all randomized and nonrandomized studies, 2.192 (95% CI, 1.329 - 3.617) for nonrandomized studies, 0.957 (95% CI, 0.622 - 1.472) for randomized studies, and 1.092 (95% CI, 0.619 - 1.927) for randomized studies that only included patients with a microbiology-confirmed bacterial infection. The researchers found no statistically significant publication bias.


Well-Tolerated by Patients


The 4 largest randomized trials compared local tolerance to topical treatments. In 1 trial, patients reported significantly more severe burning and/or stinging after applying fortified antibiotics than those who used fluoroquinolones ( P < .001).


In another study, patients reported less discomfort after ciprofloxacin use than fortified antibiotics ( P = .012), and 1 study of ofloxacin found a proportion of patients who experienced drug toxicity 5 times greater with use of fortified antibiotics ( P < .001).


One study found signs of local intolerance in only 4 patients, all of whom were treated with fortified antibiotics.


In the 3 large ciprofloxacin treatment series, 13% to 17.6% of patients experienced a "transient white crystalline precipitate in the superficial portion of the corneal epithelial defect" that was determined by liquid chromatography to be ciprofloxacin. In another series, 1 patient among 15 treated with ciprofloxacin experienced a similar effect. This did not happen with the other fluoroquinolones.


A retrospective review of 140 clinical dossiers found 9 (16.7%) major complications (5 perforations and 4 enucleations or eviscerations) among the 54 patients who received fluoroquinolones compared with only 2 (2.4%) major complications (2 enucleations, no perforations) among the 84 patients who received fortified antibiotics.


This observation was confirmed in a larger group during a longer observation period. Patients were older at presentation, but the difference remained significant ( P = .02) after controlling for age, systemic disease, and immunosuppression. This greater perforation risk could be explained by fluoroquinolone-caused alterations in corneal tectonic strength, the authors write, but this effect was not observed in larger randomized studies.


Thomas Steinemann, MD, a professor of ophthalmology at MetroHealth Medical Center and Case Western Reserve University in Cleveland, Ohio, and a clinical correspondent for the American Academy of Ophthalmology, spoke with Medscape Medical News about the study.


"Both randomized and nonrandomized studies confirm that for empiric treatment of serious corneal infections, fluoroquinolones are a logical choice as empiric therapy," Dr. Steinemann said. He added that it is important to note that fluoroquinolones work well in the vast majority of cases but that there will always be some cases (more serious and opportunistic infections) that do not respond to them.


"For the community ophthalmologist and eye care practitioner, empiric therapy with fluoroquinolones probably works well in a community practicing setting in that most practitioners are not going to have access to culture methods in their office and it may not be logistically feasible to send the patient for expensive culturing and also to send the cultures...to a laboratory for testing," Dr. Steinemann explained.


"Fluoroquinolone therapy is very useful and very practical...it's reassuring to know that these commercially available preparations are effective," he noted.


The authors and Dr. Steinemann have disclosed no relevant financial relationships.


Can J Ophthalmol. 2012;47:493-499